Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis
Menée in vitro et in vivo, cette étude montre qu'un anticorps monoclonal neutralisant la périostine, une protéine de la matrice extracellulaire, permet d'inhiber la croissance d'une tumeur de l'ovaire et le processus métastatique
Periostin (PN), an extracellular matrix protein, is reported to be overexpressed in a variety of human cancers and its functions appear to be linked to tumor metastasis. Our previous results show that engineered PN overexpression promotes ovarian tumor growth and dissemination in vivo. In the present study, we developed a neutralizing monoclonal antibody (mAb) to PN, named MZ-1, and investigated its effects on human ovarian tumor growth and metastasis. Our in vivo studies showed significant growth inhibition by MZ-1 on both subcutaneous (sc) and intraperitoneal (ip) tumors derived from the PN-expressing ovarian cancer cell line A2780. In addition, MZ-1 treatment led to a reduction of the metastatic potential of these A2780 ip tumors. The in vivo antitumor effects of MZ-1 were linked to its specific inhibition of anchorage-independent growth and survival of PN-expressing cells, as well as its neutralizing effects on PN-induced cancer cell migration and invasion. The data suggests that blocking PN expression may be a novel approach for treating the subset of invasive ovarian tumors that overexpress PN protein.
http://mct.aacrjournals.org/content/early/2011/06/11/1535-7163.MCT-11-0046.abstract 2011